David Berkowitz, MD
Pulmonary Disease · Atlanta, GANPI 1356526883
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.3%), education and travel and lodging — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Cook Incorporated at 57.3% of the total. Reporting peaked in 2022 at $9,066 and has fallen 99.1% since, to $79 in 2024.
Across 10 payments — averaging $942.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cook Incorporated$5K
- Intuitive Surgical$4K
- Johnson & Johnson$227
- Boston Scientific$114
- Cook Medical LLC$14
Across 13 payments — averaging $9969.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Galvanize Therapeutics, Inc$130K
What the payments were for
- Speaking & faculty fees$5,40057%
- Travel & lodging$5806%
- Food & beverage$4425%
- Education$3,00032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cook Incorporated | 1 | $5,400 |
| Intuitive Surgical | 5 | $3,666 |
| Johnson & Johnson | 2 | $227 |
| Boston Scientific | 1 | $114 |
| Cook Medical LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Blue Rhino$5,400
- ION$3,000
- Da Vinci Surgical System$580
- Monarch Platform$148
- ACQUIRE$114
How this compares
$9,422 in reported general payments places this provider in the 70th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Advair HfaFluticasone Propion/Salmeterol | 15 | $8,445 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,197 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $741 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Atlanta
- Colin SwensonAtlanta$255K
- Eric FlenaughAtlanta$93K
- Gregory MartinAtlanta$88K
- Victor TsengAtlanta$55K
- Ralitza MartinAtlanta$48K
- Venkatesh LakshminarayananAtlanta$33K
- Sisir AkkineniAtlanta$21K
- Gerald StatonAtlanta$21K
- Mirza AliAtlanta$16K
- Srihari VeeraraghavanAtlanta$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.